New study shows COVID-19 vaccines offer some protection against long-COVID – Yahoo Finance

Yahoo Finance’s Anjalee Khemlani joins the Live show to break down a new study that showed COVID-19 vaccines offer some protection against long-COVID.
BRAD SMITH: It was three years ago that the first COVID-19 case was diagnosed in the United States. But this morning comes with some positive data. A new study showing COVID-19 vaccines offer protection against long COVID. Yahoo Finance’s Anjalee Khemlani has the details on this one. Anj.
ANJALEE KHEMLANI: That’s right. Three years ago, the first positive case from a man in Washington State, but now here we are, entering year 4, and we still haven’t learned absolutely everything we need to know about COVID and long COVID. But new study out showing that there is protection up to 41% of a reduced risk of long COVID for anyone who gets vaccinated after being infected. That’s coming out in a new report in Jama and showing that there is some long-term benefits for these vaccines.
Now we know that there has been a lot of discussion about the vaccines and their drop in antibody levels several months after being injected. But at least we know now that there is some hope for those long COVID sufferers. There is something in these vaccines to help protect long-term. And that’s really good news because we know we’re still learning about how to deal with long COVID as well.
JARED BLIKRE: Yes, we are, and a lot to learn here. Thank you for that report, Anjalee Khemlani.
Genesis Global Capital leads the revised list that un-redacted the names of several creditors.
Three active-duty U.S. Marines, including one stationed at Camp Lejeune, were arrested for their roles in the Jan. 6, 2021 insurrection, according to the FBI.
EY Global Chairman and CEO Carmine Di Sibio speaks with Yahoo Finance at the World Economic Forum in Davos, Switzerland, about the state of the U.S. labor market, how AI and technology are impacting jobs, the outlook for his company, and his key takeaways from this year's event.
Eli Lilly stock dipped Friday after the FDA unexpectedly rejected its request for an accelerated approval of its Alzheimer's treatment.
Big Pharma stalwarts are on the brink of launching the first-ever RSV vaccines, potentially enriching the pharmaceutical stocks.
Shares of Eli Lilly were down midday Friday after the company said [U.S. regulators rejected]( its proposed new Alzheimer's disease treatment. The U.S. Food and Drug Administration said it needed more data from clinical testing, according to the company. Lilly's stock was down about 2% Friday afternoon, as the major indexes gained. Lilly's stock had advanced in recent months, partly on expectations t
While the stock market volatility continues, day in and day out, not all companies have witnessed declines in their results. In fact, many wonderful businesses are continuing to thrive in the current environment — and that includes healthcare stocks. If you're looking to add no-brainer healthcare stocks to your portfolio right now, here are two top names you'll want to consider when formulating your list of buys.
The FDA rejects Eli Lilly's (LLY) seeking accelerated approval of a new Alzheimer's drug, donanemab, due to the limited number of patients with at least 12 months of drug exposure data.
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
A class-action lawsuit accuses Simply Orange Juice of deceiving people into buying it.
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
It can be hard to know if you’re putting others at risk, but there are rules you can follow to help protect those around you.
The XBB.1.5 omicron subvariant that became dominant in the U.S. last week has gained more ground, according to data from the nation’s main health agency, accounting for 49.1% of new cases in the latest week, up from 43% a week ago. The subvariant is pulling further ahead of BQ.1.1 and BQ.1, the former dominant strains of the coronavirus that causes COVID, according to the data from the Centers for Disease Control and Prevention. In the New York region, which includes New Jersey, Puerto Rico and the U.S. Virgin Islands, XBB.1.5 accounted for 86.8% of new cases, up from 82.7% a week ago.
"We are committed to working with the FDA to ensure the fastest possible path to bring this potential medicine to patients in need," Eli Lilly said.
The regulator wants to see clinical data from at least 100 patients who have taken donanemab for a year
What happened Shares of Biomea Fusion (NASDAQ: BMEA) were up 24.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. The biotech company's stock closed at $7.
By Rachael Green, Benzinga
Should investors buy this risky biotech stock as the company moves toward bringing its first major treatment to market?
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month.